secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2025-01-13T23:59:59+00:00
Accession:  0000950103-25-000411
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics releases preliminary 2024 ZYNLONTA sales and expense data at JPM conference
--------------------------------------------------------------------------------

- Preliminary ZYNLONTA net sales and FY2024 expenses disclosed at JPMorgan Healthcare Conference; no specific figures in filing.
- Forward-looking statements reference expected cash runway into mid-2026 and potential to grow ZYNLONTA revenue.
- Presentation highlights pipeline including LOTIS 5, LOTIS 7, ADCT-602, and exatecan-based solid tumor platform.
- ZYNLONTA is approved for relapsed/refractory large B-cell lymphoma after two prior therapies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000095010325000411/0000950103-25-000411-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000095010325000411/dp223356_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-25-000411

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer